Xtalks’ Post

🌐 https://www.docqc.com 🌟 Discover the Future of Clinical Trials! 🌟 Our innovative FSP solutions are here to revolutionize your research process. From protocol design to regulatory compliance, we offer a suite of services designed to streamline every stage of your clinical trial. Our expert team is committed to accelerating drug development, enhancing patient outcomes, and advancing medical science. Embrace a tailored approach with significant budget savings. Let's bring new therapies to market, together. Explore how we can support your journey to innovation. Visit our site now! 🔬💡 #ClinicalTrials #InnovationInHealth #FSPSolutions #DrugDevelopment #MedicalScience #PatientOutcomes #HealthcareTechnology #ClinicalResearch #ProtocolDesign #TrialOperations #DataManagement #RegulatoryCompliance #PharmaIndustry #Biotech #HealthTech #ResearchAndDevelopment #FutureOfHealthcare #ClinicalInnovation #TherapyAdvancement #PartnerInScience

🌐 https://www.docqc.com 🌟 Discover the Future of Clinical Trials! 🌟 Our innovative FSP solutions are here to revolutionize your research process. From protocol design to regulatory compliance, we offer a suite of services designed to streamline every stage of your clinical trial. Our expert team is committed to accelerating drug development, enhancing patient outcomes, and advancing medical science. Embrace a tailored approach with significant budget savings. Let's bring new therapies to market, together. Explore how we can support your journey to innovation. Visit our site now! 🔬💡 #ClinicalTrials #InnovationInHealth #FSPSolutions #DrugDevelopment #MedicalScience #PatientOutcomes #HealthcareTechnology #ClinicalResearch #ProtocolDesign #TrialOperations #DataManagement #RegulatoryCompliance #PharmaIndustry #Biotech #HealthTech #ResearchAndDevelopment #FutureOfHealthcare #ClinicalInnovation #TherapyAdvancement #PartnerInScience

Michelle Gyzen, Senior Director with IQVIA’s Regulatory Affairs and Drug Development, was interviewed by Authority Magazine on how AI technologies are revolutionizing the regulatory industry. Read her in-depth interview here: https://bit.ly/3zEQnkP #regulatoryaffairs #regulatoryoperations #regulatoryintelligence #regulatorytechnology

As companies embark upon developing clinical trials, it is important to consider all the options you have to optimise your approach, especially with a view to the timely achievement of the key goals of drug registration and reimbursement. The latter, often referred to as the final hurdle, was not usually considered by the R&D teams of the past. However, to optimally commercialise the innovative technologies now appearing in the marketplace, securing reimbursement is crucial, and that requires the right trial design.  As this knowledge may not be available, or well developed, ‘in house’, having an independent team of advisors such as the team at Axis Health Co. is an invaluable resource when considering trial design. With their decades of experience in this area they can help you with trial-related questions such as: Are the endpoints surrogate, or final? What sort of data will be generated? Will Bayesian/adaptive statistics help, or hinder, you? Does the control arm meet the needs for reimbursement submissions? If not, will indirect comparisons be required? Is the right data to support comparison with future reimbursement competitors being included?  If you’re thinking about clinical trial design for your new technology, Axis Health Co would love to have a conversation with you, and to partner with you to provide independent, impartial advice and insights on how to make this aspect of your strategic planning as powerful as the products and teams you have. Contact us to start the conversation: contactus@axishealthco.com #clinicaltrials #medicalresearch #pharmaceuticals #biotech #axishealthco #clinicalresearch

In her latest Forbes article, Eileen Faucher explains the business case for expanding diversity in clinical trials. At BTH, we have developed methodologies to gain insights into best practices in this regard. Reach out to learn how better patient representation in clinical trials can be a lever of sustained competitive advantage. Eileen@brasstackshealth.com #competitiveintelligence #forbes #healthequity #clinicaltrialdiversity

Uncover the formidable synergy as #CROs and #eClinical companies join forces to transform your #clinicaltrials. Download #whitepaper at: https://hubs.li/Q02jnYXC0 Specialized in protocol design, patient recruitment, and regulatory compliance, Contract Research Organizations (CROs) provide invaluable support in clinical trials. Simultaneously, eClinical companies, equipped with advanced data management solutions and cutting-edge technologies, offer the necessary tools and insights for efficient trial execution. Together they have tremendous potential to transform your #clinicaltrials. #CTMS #eTMF #EDC #RTSM #Safety #PV #Pharmaceutical #Biotechnology #MedicalDevices #Diagnostics #Cloudbyz #ClinicalTrials #CROs

PureSoftware has been building central clinical trial platforms for global technology companies, to enable accelerated drug development through optimized, faster, and efficient clinical trial processes. Read one of the case studies here: https://lnkd.in/gamBY6i5 #PureSoftware #lifesciences #lifescienceandhealthcare #healthcareinnovation #drugdevelopment #globaltechnology #clinicaltrials #casestudies #successstories #linkedin

Discover the world of clinical labeling in drug development. From understanding its significance to exploring target labeling and safety information, gain insights into streamlined processes. Explore Freyr's expertise in clinical labeling. https://lnkd.in/gjtPYEAB   #ClinicalLabeling #DrugDevelopment #TargetLabeling #LabelingCompliance #FreyrSolutions  

𝙃𝙤𝙬 𝘼𝙄 𝙞𝙨 𝙗𝙚𝙞𝙣𝙜 𝙪𝙨𝙚𝙙 𝙩𝙤 𝙖𝙘𝙘𝙚𝙡𝙚𝙧𝙖𝙩𝙚 𝙘𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙩𝙧𝙞𝙖𝙡𝙨 Application of #AI to biopharma R&D have largely focused on the drug discovery & development phases. But human trials is where the costs tend to explode. Trial design, patient recruitment, trial site selection...are all crucial steps that are still very much done manually and will significantly impact trial outcomes (i.e. can we get our drug approved by the FDA?) This Nature article delves into the impact of AI on these limiting steps (see link below). If you are a founder building in that space, do not hesitate to reach out to us at Kurma Partners! #healthtech #clinicaltrials #artificialintelligence Philippe Peltier Alain HORVAIS Amine MAROUF Laura Achach Loubaba El Ayoubi

With approximately 90% of candidates entering clinical trials failing to achieve regulatory approval, understanding the reasons behind these failures is crucial for companies aiming to future-proof their product candidates. Read our latest whitepaper, “Learning the Lessons of Failure: How to improve the economics of Life Sciences R&D” and dive deep into eight real-world case studies that reveal the challenges and invaluable lessons learned from drug development programs. View here: https://ow.ly/alUj30sBRwA #clinicaltrial #drugdevelopment #regulatory